Study wrapper · #344
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent.
Editor's note
A pointedly critical review arguing that bremelanotide (PT-141) and flibanserin were approved on weak and shifting evidence. The authors contend that in trials flibanserin yielded roughly one extra enjoyable sexual experience every two months and bremelanotide none, and that primary outcomes shifted mid-program amid industry-linked advocacy and conflicts of interest. This is analysis and argument, not new trial data, and it reflects a defined skeptical viewpoint — but it is a valuable counterweight to manufacturer-adjacent literature and broadly consistent with independent re-analyses showing modest benefit and frequent side-effect-driven dropout. The core tension is real: bremelanotide's improvements on desire and distress scales reached statistical significance, yet their clinical meaningfulness is contested. Readers should hold both facts together — approval and statistical significance on one side, disputed real-world benefit and a notable side-effect burden on the other. A useful corrective to read alongside the pivotal trial reports.
Plain-language abstract
This is a critical opinion review of two FDA-approved drugs for low sexual desire in women: flibanserin (Addyi, 2015) and bremelanotide (PT-141 / Vyleesi, 2019). The authors examined the outcome measures and trial data used for approval. They argue the benefits were very small — flibanserin produced, on average, about one additional enjoyable sexual experience every two months, and by their reading bremelanotide produced no extra such experiences. They also say the trials changed which outcomes they emphasized partway through, and that the approvals were shaped by industry-funded advocacy and by experts and patients with conflicts of interest. They suggest bremelanotide gained approval largely by following the precedent flibanserin set, despite what they describe as even weaker effects. The authors call for regulators to reconsider these approvals and to better weigh conflicts of interest and genuinely meaningful benefit. This article presents a viewpoint and re-interpretation rather than new experimental data.